Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Repeated transfusions: how do we balance benefit and risk in chronic hematologic diseases?
Every year, thousands of patients live thanks to repeated transfusions… but at what long-term cost?
In many chronic hematologic diseases (sickle cell disease, myelodysplastic syndromes, leukemias), red blood cell concentrates are essential to correct anemia
and maintain quality of life.
However, repeated transfusions carry well – documented risks: alloimmunization, making future transfusions more complex, and iron overload, which can lead to hepatic, cardiac, and endocrine complications that are often underestimated.
Iron chelation therapy then becomes necessary, yet burdensome.
Other challenges also arise, such as delayed hemolytic transfusion reactions, sometimes severe, and variability in transfusion thresholds, raising questions about optimal use.
Current guidelines emphasize a more restrictive and individualized approach, tailored to each patient’s condition and disease.
Transfusion is no longer just a supportive act – it is a true therapeutic lever, requiring careful balance between immediate clinical benefit and long-term impact.
Should we more broadly rethink transfusion strategies to better anticipate their chronic consequences?”
More posts featuring Maxime Dely on Hemostasis Today.
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care